Articles From: Celanese to Present at Goldman Sachs Basic Materials Conference 2014 to Centamin plc: Director Acquisition of Shares


2014/5/14
Celanese Corporation (NYSE: CE), a global technology and specialty materials company, today announced that Mark Rohr, chairman and chief executive officer, will address investors at the Goldman Sachs Basic Materials Conference 2014 in New York City on Tuesday, May 20, 2014, at 2:20 p.m. Eastern time.
Sign-up for Celanese to Present at Goldman Sachs Basic Materials Conference 2014 investment picks
2014/4/30
Celanese Corporation (NYSE: CE), a global technology and specialty materials company, today announced that Scott Richardson, vice president & general manager intermediate chemistry, will address investors at the 5th Annual Wells Fargo Industrial & Construction Conference in New York City on Wednesday, May 7, 2014, at 1:10 p.m. Eastern time.
Sign-up for Celanese to Present at the 5th Annual Wells Fargo Industrial & Construction Conference investment picks
EWING, N.J., May 12, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX) , a pharmaceutical company developing new and more effective therapies to treat cancer, today reported business highlights and financial results for the first quarter ended March 31, 2014.
Sign-up for Celator(R) Pharmaceuticals Announces Business Update and First Quarter 2014 Financial Results investment picks
EWING, N.J., May 12, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. , (Nasdaq:CPXX) , a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it has entered into a loan agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) , a specialty finance company that provides customized debt financing to companies in life sciences and technology-related markets.
Sign-up for Celator(R) Pharmaceuticals Secures Loan Agreement With Hercules Technology Growth Capital investment picks
EWING, N.J., May 22, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX) , a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the Third Annual Marcum MicroCap Conference, New York, NY, on Thursday, May 29, 2014, at 2:00 p.m. EDT.
Sign-up for Celator(R) Pharmaceuticals to Present at Third Annual Marcum MicroCap Conference investment picks
EWING, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. , (Nasdaq:CPXX) , a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it will host a conference call and live audio webcast on Monday, May 12, 2014 at 4:30 p.m. ET to report first quarter 2014 financial results.
Sign-up for Celator(R) Pharmaceuticals to Report First Quarter 2014 Financial Results on May 12, 2014 investment picks
2014/5/6
Premier specialty sporting goods retailer offers tips and products to support women's health LOS ANGELES , May 6, 2014 /PRNewswire/ -- Stand up for good health during National Women's Health Week May 11 to 17 .
Sign-up for Celebrate National Women's Health Week With Sport Chalet investment picks
2014/5/23
Celestica Completes a Program Share Repurchase Canada NewsWire TORONTO , May 23, 2014 /CNW/ - Celestica Inc. (NYSE, TSX: CLS), a global leader in the delivery of end-to-end product lifecycle solutions, today announced that it completed a program share repurchase (a PSR) under its previously announced Normal Course Issuer Bid.
Sign-up for Celestica Completes a Program Share Repurchase investment picks
2014/5/23
TORONTO , May 23, 2014 /PRNewswire/ - Celestica Inc. (NYSE, TSX: CLS), a global leader in the delivery of end-to-end product lifecycle solutions, today announced that it completed a program share repurchase (a PSR) under its previously announced Normal Course Issuer Bid.
Sign-up for Celestica Completes a Program Share Repurchase investment picks
SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN) , a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that its lead product candidate, MYDICAR ® , has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative.
Sign-up for Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure investment picks
Conference Call Scheduled for May 14, 2014 at 9:00 ET NETANYA, Israel , April 29, 2014 /PRNewswire/ -- Cellcom Israel Ltd.
Sign-up for Cellcom Israel Schedules First Quarter 2014 Results Release for May 14, 2014 investment picks
HAMPTON, N.J., May 1, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2014.
Sign-up for Celldex Reports First Quarter 2014 Results investment picks
HAMPTON, N.J., May 14, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 in Chicago.
Sign-up for Celldex Therapeutics Announces Varlilumab (CDX-1127) Phase 1 Clinical Data to be Presented at ASCO Annual Meeting 2014 investment picks
HAMPTON, N.J., May 2, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Deutsche Bank 39 th Annual Healthcare Conference on Wednesday, May 7, 2014 at 11:20 a.m. ET at the InterContinental Hotel in Boston and at the Bank of America Merrill Lynch 2014 Healthcare Conference on Wednesday, May 14, 2014 at 4:20 p.m. PT at the Encore at the Wynn in Las Vegas.
Sign-up for Celldex to Present at Two Upcoming Investor Conferences investment picks
MADISON, Wis., April 30, 2014 (GLOBE NEWSWIRE) -- Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL) today announced the launch of iCell® DopaNeurons, the company's neural floor plate-derived midbrain dopaminergic neurons generated from human induced pluripotent stem cells (iPSCs). Key points : Dopaminergic neurons, specifically those located in the floor plate-derived midbrain, are implicated in neurological disorders such as Parkinson's disease and schizophrenia; thus iCell DopaNeurons provide a highly relevant in vitro model to investigate these types of pathologies.
Sign-up for Cellular Dynamics Announces Launch of iCell(R) DopaNeurons, Neural Floor Plate-Derived Midbrain Dopaminergic Neurons investment picks
MADISON, Wis., April 28, 2014 (GLOBE NEWSWIRE) -- Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL) today announced that the company will host a webcast and conference call to discuss its financial results for the first quarter ended March 31, 2014.
Sign-up for Cellular Dynamics to Host First Quarter 2014 Financial Results Webcast and Call investment picks
MADISON, Wis., May 7, 2014 (GLOBE NEWSWIRE) -- Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL) today announced that Chief Executive Officer Bob Palay will present at the Bank of America Merrill Lynch 2014 Health Care Conference to be held May 13 - 15, 2014, in Las Vegas.
Sign-up for Cellular Dynamics to Present at Bank of America Merrill Lynch 2014 Health Care Conference investment picks
MADISON, Wis., May 21, 2014 (GLOBE NEWSWIRE) -- Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL) , a developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that Chief Executive Officer Bob Palay will present at the Jefferies 2014 Global Healthcare Conference to be held in New York from June 2 - 5, 2014.
Sign-up for Cellular Dynamics to Present at Jefferies 2014 Global Healthcare Conference investment picks
- On Track for Study Participation in Major HCC Markets Worldwide - LAWRENCEVILLE, N.J. , May 21, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced it has received regulatory clearance to initiate its Phase III OPTIMA Study at clinical trial sites in Taiwan , Hong Kong , South Korea and Canada.
Sign-up for Celsion Advances Global Regulatory Efforts in Support of Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer investment picks
LAWRENCEVILLE, N.J. , May 1, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss first quarter 2014 financial results at 11:00 a.m. EDT on Thursday, May 8, 2014 .
Sign-up for Celsion Corporation to Hold First Quarter 2014 Financial Results Conference Call on Thursday, May 8, 2014 investment picks
NEW YORK and LONDON, May 14, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX) , an emerging growth, development-stage biotech company, announced today that the annual general meeting of its shareholders will be held on Thursday, June 19, 2014 at 10:00 a.m. (Local Time, BST in UK), at 53 Davies Street, Mayfair, London W1K 5JH, United Kingdom.
Sign-up for Celsus Therapeutics PLC Announces Details of Annual General Meeting of Shareholders investment picks
FARMINGDALE, N.Y. , May 14, 2014 /PRNewswire/ -- Cemtrex, Inc. (OTC: CTEI) today announced that the company has received new orders in excess of $4,000,000 across its three business divisions: Monitoring Instruments & Products, Rob Cemtrex, and Environmental systems.
Sign-up for Cemtrex Receives $4.4 Million in New Orders investment picks
FARMINGDALE, N.Y. , May 22, 2014 /PRNewswire/ -- Cemtrex (OTCBB: CTEI) announced today that the company will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel.
Sign-up for Cemtrex, Inc. To Present At The Third Annual Marcum MicroCap Conference investment picks
2014/4/29
SANTIAGO, Chile , April 29, 2014 /PRNewswire/ -- Cencosud S.A. (NYSE: CNCO) announced today the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2013 (the " 2013 Annual Report ") with the U.S. Securities and Exchange Commission (the " SEC "). The 2013 Annual Report can be accessed by visiting the SEC's website www.sec.gov and can also be found at Cencosud's website www.cencosud.com , under the Public Filings tab.
Sign-up for Cencosud S.A. Announces Filing of its Annual Report Form 20-F for 2013 investment picks
Cenovus reports voting results of election of directors Canada NewsWire CALGARY , April 30, 2014 /CNW/ - Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) announced that at its annual meeting of shareholders held on April 30, 2014 each of the nine nominees proposed as directors and listed in its management proxy circular dated March 7, 2014 were elected as directors.
Sign-up for Cenovus reports voting results of election of directors investment picks
2014/5/13
CALGARY , May 13, 2014 /PRNewswire/ - John Brannan , Executive Vice-President & Chief Operating Officer, will be presenting at the Citi Global Energy and Utilities Conference on Wednesday, May 14, 2014 at 6 a.m. MT ( 8 a.m. ET ) in Boston .
Sign-up for Cenovus to present at the Citi Global Energy and Utilities Conference investment picks
2014/5/5
Workshop on Improving Lives Through Payer/Provider Collaboration AUSTIN, Texas , May 5, 2014 /PRNewswire/ -- Cenpatico is pleased to announce that Michelle Thomas , Clinical Director, will co-present with Thresholds' Mark Furlong, VP of Clinical Operations, at this year's National Conference in Washington, D.C. , May 5-7 .
Sign-up for Cenpatico to Present at the National Council for Behavioral Health Conference in Washington, D.C., May 5 -7, 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1116020&ProfileId=051205&sourceType=1 PERTH, AUSTRALIA --
Sign-up for Centamin PLC Announces Results for the Quarter Ended 31 March 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1111054&ProfileId=051205&sourceType=1 PERTH, AUSTRALIA --
Sign-up for Centamin PLC: Application for Listing of Ordinary Shares investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1117858&ProfileId=051205&sourceType=1 PERTH, AUSTRALIA --
Sign-up for Centamin plc: Director Acquisition of Shares investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Celanese to Present at Goldman Sachs Basic Materials Conference 2014 to Centamin plc: Director Acquisition of Shares
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry